Physician profile
Ryan P Ames
NPI 1265638217
$4,582.71
in general payments reported to CMS, 2019-2025
20 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $504 · 2021: $946 · 2022: $1,377 · 2023: $801 · 2024: $390 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.93 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,228.14 | 2019-2024 | Precision 1, Total30 |
| Horizon Therapeutics Plc | $960.35 | 2022-2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $648.43 | 2019-2025 | Acuvue |
| Lumenis Be INC | $381.78 | 2023 | Optilight |
| Bausch & Lomb Americas INC. | $341.98 | 2022-2024 | Infuse, Miebo, Biotrue One Day |
| Abbvie INC. | $208.81 | 2022-2023 | Alphagan P, Lumigan |
| Dompe US, INC. | $124.99 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $87.77 | 2019-2021 | |
| Glaukos Corporation | $65.42 | 2022 | |
| Lkc Technologies, INC. | $63.75 | 2023 | |
| Mallinckrodt Hospital Products INC. | $63.42 | 2024-2025 | Acthar |
| Amgen INC. | $58.11 | 2024-2025 | Tepezza |
| Allergan, INC. | $42.19 | 2021-2022 | |
| Oyster Point Pharma, INC. | $39.81 | 2023-2024 | Tyrvaya, Ryzumvi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $37.89 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $28.90 | 2021 | |
| Thea Pharma INC. | $28.78 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $25.82 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $21.83 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Ames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.